Bayer hedges its previous bets in microbes by partnering with Pivot Bio

November 9, 2018
Emerging Ecosystems in Agrifood and Health More...
12744 thumb square
by Joshua Haslun
Very important

Pivot stated that the partnership will focus on the development of Bradyrhizobium strains that improve nitrogen fixation in leguminous crops, with expectations for field trials by 2021. The move builds on the company's momentum, as it recently released the first-ever nitrogen fixing biofertilizer, PROVEN, to supplement corn fertilization in the U.S. Pivot's pipeline includes the development of similar products for rice and wheat. A solution for soybeans through Bayer, which is already in the microbe game with Joyn Bio, will greatly expand the company's reach in the sustainable agriculture market. Clients should jump on the opportunity to build synergies between conventional crop nutrition strategies and sustainable nitrogen-fixing microbes.

For the original news article, click here .

Further Reading

Benson Hill Biosystems' acquisition targets future developments in soybean quality

News Commentary | March 20, 2019

After the establishment of many partnerships, Benson Hill Biosystems' acquisition of Schillinger Genetics' assets indicates an internal development path. Benson Hill's breeding and genetic editing platforms and internally developed traits are well‑positioned to improve on Schillinger's (also known ... Not part of subscription

Cibus raises $70 million Series C

News Commentary | July 2, 2018

Cibus completed a Series C round for $70 million. The company uses a nonregulated gene editing technique. To date, Cibus has targeted single herbicide‑tolerant traits in rotation crops like canola and flax. The company has found success because competitors have been focusing on more complex trait ... Not part of subscription


Company Snapshot | November 13, 2017

The company was started by John Ryals, Mike Koziel, Eric Ward, and Scott Uknes in 2012. To date, the company has raised approximately $54 million in venture capital and private equity funding, most recently raising a $34.5 million Series B in August 2015. Among its investors, we emphasize Novozymes... Not part of subscription